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Divergent Effects of Disease-Associated Mutations on Type 2 Ryanodine
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Type 2 ryanodine receptor (RyR2) is a Ca2þ release channel in the sarco-
plasmic reticulum and plays a pivotal role in excitation-contraction coupling
in heart. RyR2 is the major target for arrhythmogenic diseases, e.g., catechol-
aminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic
right ventricular cardiomyopathy (ARVC). To date, over 150 mutations have
been identified in the RyR2 gene of CPVT and ARVC patients. It is widely
believed that CPVT and ARVC mutations cause hyperactivation of the
Ca2þ-induced Ca2þ release (CICR), resulting in abnormal Ca2þ homeostasis
in cardiac muscle. CICR shows biphasic Ca2þ dependence against cytoplasmic
Ca2þ, thus the activity can be determined by three parameters: sensitivity to
activating Ca2þ, sensitivity to inactivating Ca2þ, and the gain (i.e., peak
activity). In addition, CICR is also regulated by luminal Ca2þ; high luminal
Ca2þ activates CICR, and vise versa. However, it remains unclear how the
disease-associated mutations affect these parameters. In this study, we ex-
pressed RyR2 channels carrying several CPVT/ARVC mutations in HEK cells
and tested their CICR by live-cell Ca2þ imaging and [3H]ryanodine binding.
Our results suggest that the disease-associated mutations divergently affects
the parameters of CICR depending on the sites for mutation. The underlying
molecular mechanism will be discussed.
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Ryanodine receptors (RyRs) are intracellular calcium-release channels of the
endo/sarcoplasmic reticulum that are critical to the muscle excitation-
contraction coupling. Mutations in the cardiac isoform (RyR2) are linked to
life-threatening arrhythmias, such as catecholaminergic polymorphic ventricu-
lar tachycardia (CPVT), known for a sudden cardiac arrest. RyR2 is the target
for over 150 disease-associated mutations. Here, we present the 2.0A˚ crystal
structure of the N-terminal region of RyR2 (residues 1-547), an area containing
29 distinct disease-associated mutations. The protein folds up in three individ-
ual domains similarly to its counterpart in the skeletal muscle, RyR1, but con-
tains a unique central chloride anion that holds together the three domains. The
CPVT-associated mutant R420Q targets one of the Arginines coordinating the
anion and ablates chloride binding. The crystal structure of the mutant shows
reorientations in the first two domains relative to the third, likely destabilizing
intersubunit interactions in the context of an intact channel. Chloride anion
binding may represent one of the ways RyR2 uses to regulate channel opening.
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To date, classical mechanisms of arrhythmogenesis in CPVT require sponta-
neous Ca2þ release via hyperactive RyR2 channels affected by gain-of-
function mutation. Here, we report novel arrhythmia mechanisms in a
CPVT-linked RyR2-A4860G mutation that depresses channel activity. Murine
RyR2-A4860G cDNA was expressed in CHO cells to the same level than wild-
type (WT), but recombinant RyR2-A4860G protein displayed dramatically
reduced channel activity by [3H]ryanodine binding assay and direct single
channel activity recording. Mice heterozygous for RyR2-A4860G mutation
(RyR2-A4860Gþ/-) exhibited basal bradycardia without cardiac structural
alterations; no homozygotes were detected at birth, indicating the mutation is
phenotypically too strong to be harbored in two alleles. Anesthetized RyR2-
A4860Gþ/- mice injected with arrhythmogenic cocktail (120mg/kg caffeine,
2mg/kg epinephrine) displayed ECG alterations of QRT alternans, premature
ventricular complexes and bidirectional ventricular tachycardia, while ECGs
of WT mice remained uneventful. Simultaneous recording of action potentials
(APs) and [Ca2þ]i transients in isoproterenol-stimulated RyR2-A4860G
þ/-ventricular myocytes showed prolonged APs and interspaced bursts of altered
Ca2þ release consisting of normal peak followed by a second, prolonged phase
of release. Remarkably, early afterdepolarizations (EADs) were observed only
during the prolonged phase of Ca2þ release, and were abolished by NCX inhib-
itor CB-DMB or intracellular Ca2þ chelator EGTA. SR Ca2þ load was higher in
RyR2-A4860Gþ/- cells before EADs but decreased to levels comparable to WT
after EADs. Simultaneous recording of ICa,L and [Ca
2þ]i transients showed
decreased transient amplitude and prolonged Ca2þ-dependent-inactivation of
ICa,L in RyR2-A4860G
þ/- cells. In conclusion, RyR2-A4860G loss-of-function
mutation decreases Ca2þ release amplitude and impairs ICa,L inactivation, both
of which gradually overload SR. The resultant SR overload then causes bursts
of prolonged Ca2þ release, activating electrogenic NCX activity during
APs and triggering EADs. The RyR2-A4860G mutation reveals novel path-
ways by which RyR2 channels engage membrane currents to produce
life-threatening arrhythmias.
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We previously showed that ablation of the cardiac Ca2þ release channel/
ryanodine receptor (RyR2) phosphorylation at Ser2808 (RyR2-S2808A) has
no functional impact on cardiac performance and/or heart failure progression.
In this study, we investigated whether this lack of effect may be due to compen-
satory mechanisms involving altered phosphorylation of the nearby Ser2814
CaMKII phospho-site. We generated a new mouse model where Ser2808 and
Ser2814 were genetically replaced by Alanine (RyR2-S2808A/S2814A). Anes-
thetized RyR2-S2808A/S2814A mice have normal ejection fraction at baseline
compared to wild type (WT) mice (55.152.6% vs. 55.952.4%, respectively,
n=7/group) but exhibit ~20% increase in heart rate (553533 vs. 460528
bpm, p<0.05, n=8/group). Langendorff-perfused hearts from both, RyR2-
S2808A/S2814A and WT mice displayed an equally robust increase in the
amplitude of isoprenaline (200nM)-stimulated LV contractions (60% and
63% above control in mutant and WT hearts, respectively, n=10/group,
p=0.7). In agreement with the whole-heart results, isoproterenol (100nM)-stim-
ulated RyR2-S2808A/S2814A myocytes displayed a comparable increase in
Ca2þ transient amplitude and sarcoplasmic reticulum (SR) Ca2þ content than
WT cardiomyocytes. Nevertheless, ablation of the S2808/S2814 phospho-
sites significantly decreased RyR2 refractoriness measured by a 2-pulse proto-
col (14257 vs. 19456 ms in the S2808A/S2814A and WT, respectively, n=7,
p<0.01). This effect was associated with a ~27% increase in SR Ca2þ leak
(3.2250.2 vs. 2.5350.2 DF/F0.100mm
1.s1 in the RyR2-S2808A/S2814A
and WT myocytes, respectively, n=17/group, p<0.05) causing earlier, faster
and more frequent spontaneous Ca2þ waves. Interestingly, 60% of RyR2-
S2808A/S2814A and 40% of the WT Langendorff-perfused hearts (n=10
each) exhibited arrhythmias upon isoprenaline stimulation. In conclusion, our
data show that inhibition of S2808 and S2814 phosphorylation leaves intact
the b-adrenergic response of the heart but accelerates RyR2 refractoriness,
increasing SR Ca2þ leak and promoting arrhythmic events.
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Cardiac Ryanodine Receptor (RyR2) is the major intracellular calcium release
channel located in the sarcoplasmic reticulum. A large number of mutations in
RyR2 have been linked to inherited cardiac arrhythmias (CPVT, catecholamin-
ergic polymorphic ventricular tachycardia and IVF, idiopathic ventricular
fibrillation) and sudden cardiac death. We previously demonstrated that in
contrast to CPVT RyR2mutations, the IVF RyR2mutation A4860G suppresses
RyR2 function. However, A4860G represents the only IVF RyR2 mutation that
has been functionally characterized to date. To determine how common
suppression-of-function RyR2 mutations are, we systematically characterized
27 RyR2 mutations that are associated with IVF or sudden cardiac death.
Each of these mutations was generated by site-directed mutagenesis and
expressed in HEK293 cells. Ca release assays revealed that 7 of these mutations
suppress or abolish caffeine-induced Ca release. Single cell Ca imaging studies
also indicated that these suppression- or loss-of-function RyR2 mutations
